ECS Botanics HoldingsASX:ECS +66.67% 14-Day RSI is 56.06 as of Jul. 05, 2026. The stock has 9 warning signs investors should review. Among 1,046 Drug Manufacturers companies, ECS Botanics Holdings ranks worse than 66.16% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
ECS Botanics Holdings 14-Day RSI Related Terms
ASX:ECS vs ZTS, UTHR: 14-Day RSI Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, ECS Botanics Holdings's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ECS Botanics Holdings 14-Day RSI vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ECS Botanics Holdings's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where ECS Botanics Holdings's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ECS Botanics Holdings (ASX:ECS) has a 14-Day RSI of 56.06 as of Jul. 05, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on ECS Botanics Holdings and its competitors. According to the industry distribution chart, ECS Botanics Holdings ranks #692 out of 1046 companies in the Drug Manufacturers industry, placing it in the top 66.2%.
Is ECS Botanics Holdings' 14-Day RSI too high?
ECS Botanics Holdings' current 14-Day RSI is 56.06. The Drug Manufacturers industry median 14-Day RSI is 50.74. ECS Botanics Holdings' value of 56.06 is 10.5% above this industry median. Based on the distribution chart, ECS Botanics Holdings ranks #692 out of 1046 companies in the Drug Manufacturers industry, which is below the industry midpoint.
How does ECS Botanics Holdings' 14-Day RSI compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, ECS Botanics Holdings ranks #692 out of 1046 companies for 14-Day RSI. This places ECS Botanics Holdings in the lower half of its industry. The industry median 14-Day RSI is 50.74. ECS Botanics Holdings' value of 56.06 is 10.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Drug Manufacturers company?
The median 14-Day RSI among Drug Manufacturers companies is 50.74, based on 1,046 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ECS Botanics Holdings's current 14-Day RSI of 56.06 is 10.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on ECS Botanics Holdings and its competitors. For the Drug Manufacturers industry, the median 14-Day RSI is 50.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ECS Botanics Holdings's current 14-Day RSI is 56.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ECS Botanics Holdings stock overvalued right now?
Based on GuruFocus' analysis, ECS Botanics Holdings (ASX:ECS) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.02, compared to a current price of A$0.01 — trading 75% below its estimated fair value. The current 14-Day RSI is 56.06 and 10.5% above the Drug Manufacturers industry median of 50.74. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For ECS Botanics Holdings (ASX:ECS), the current 14-Day RSI is 56.06 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ECS Botanics Holdings Ltd is an Australian medicinal cannabis cultivator and manufacturer located in Northwest Victoria. The company utilizes progressive cultivation methodologies to produce quality medicine in a sustainable way, adopting regenerative and organic horticultural practices and renewable energy sources. Licensed by the Therapeutic Drug Administration to manufacture PIC/S GMP certified products, the company provides quality, affordable medicinal cannabis, supplying both local and overseas markets.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ECS has been successfully added to your